SCHEMBL488153

SCHEMBL488153

CC(Oc1cc(-c2ccc(NC(=O)N3CCN(C)CC3)cc2)cnc1N)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.64

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 6/20 0.64
MET P08581 14/20 0.64
MAP4K2 Q12851 1/20 0.64
MAP3K1 Q13233 1/20 0.64
AAK1 Q2M2I8 1/20 0.64
Q6ZSR9 Q6ZSR9 1/20 0.64
MAP4K5 Q9Y4K4 1/20 0.64
AXL P30530 1/20 0.60
JAK2 O60674 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30454773 1.00 ALK (0.64) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL488650 0.95 ALK (0.57) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL30453113 0.95 ALK (0.57) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL10215655 0.88 MET (0.65) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL10215653 0.88 MET (0.65) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL487856 0.88 MET (0.65) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL30454989 0.88 MET (0.65) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL487918 0.88 MET (0.65) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL30453258 0.88 MET (0.65) ALKMETMAP4K2MAP3K1AAK1
SCHEMBL30452512 0.88 MET (0.78) ALKMETMAP4K2MAP3K1AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4695588-B2 2011-06-08 JP claimed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 ALK 138/4885MET 1/4885MAP4K2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.